Lifecare ASA is a Norway-based company that develops miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers. Lifecare's activities are concentrated on the development of sensor for use as a medical product, initially the sensor Sencell for continuous monitoring of glucose (blood sugar) for people with diabetes. The technology is suitable for detecting and measuring a wide range of molecules that can occur in the human body, based on variations in osmotic pressure.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-19 Earnings release - Q2 2026

More about the company

Market Cap	95.4M 10.04M 8.69M 8.11M 7.44M 14M 956M 14.22M 95.2M 37.36M 479M 37.72M 36.89M 1.58B	P/E 2026 *	-0.84x	P/E 2027 *	-1.14x
Enterprise Value	131M 13.84M 11.97M 11.18M 10.25M 19.28M 1.32B 19.59M 131M 51.46M 660M 51.95M 50.82M 2.18B	EV / Sales 2026 *	-	EV / Sales 2027 *	26.7x
Free-Float	89.66%	Yield 2026 *	-	Yield 2027 *	-

07-02	Lifecare Completes Production Transfer and Provides Update on Longevity Programme	CI
06-29	Lifecare Transfers Operations from Germany to Norway, UK	MT
06-26	Lifecare ASA Discontinues Operations of Lifecare Germany GmbH	CI
06-10	Lifecare Completes First Six-Month Implant Evaluation With Continued Functionality and No Adverse Biological Response	CI
05-15	Lifecare ASA, Q1 2026 Earnings Call, May 15, 2026
05-15	Lifecare ASA Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-15	Lifecare Q1 operating loss NOK 31.5 mln	RE
04-23	Lifecare ASA Approves Board Appointments	CI
03-26	Lifecare ASA Announces Operational Restructuring And Centralization Of Operations	CI
03-26	Lifecare ASA Announces Discontinuation of the Business Operations of Lifecare Germany GmbH	CI
03-26	Lifecare ASA to Close German Operations, Consolidate Activities Under Planned Centralization	MT
03-16	Lifecare Chief Scientific Officer to Step Down	MT
03-14	Andreas Pfützner to Step Down as Chief Scientific Officer of Lifecare ASA	CI

07-02	LIFE: Update on production transfer and longevity programme	AQ
06-26	LIFE: Operational update regarding Lifecare Germany GmbH (i.L)	PU
06-22	LIFE: Independent tissue analysis confirms no adverse tissue response after six months of implantation	AQ
06-12	Lifecare ASA: Final results following expiry of exercise period for Warrants Series 2 issued in connection with Rights Issue	PU
06-10	Lifecare ASA: Mandatory notification of trade	PU

Manager	Title	Age	Since
Joacim Holter CEO	Chief Executive Officer	50	07/09/2020
Petter Nielsen DFI	Director of Finance/CFO	-	01/04/2026
Torsten Ernst PRN	Corporate Officer/Principal	-	01/03/2024

Director	Title	Age	Since
Trine Teigland BRD	Director/Board Member	-	26/06/2020
Morten Foros Krohnstad CHM	Chairman	-	08/05/2021
Lutz Heinemann BRD	Director/Board Member	-	20/11/2020

Lifecare AS Stock Oslo Bors

Stocks

NO0010591191

Biotechnology & Medical Research

Valuation: Lifecare AS

Latest news : Lifecare AS

Last Transcript: Lifecare AS

Analysts' recommendations: Lifecare AS

Press Releases: Lifecare AS

News in other languages: Lifecare AS

Managers and Directors: Lifecare AS

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIFECARE AS	-.--%	-4.31%	-	-	10.04M
LONZA GROUP AG	+0.99%	+1.78%	+4.07%	+16.73%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.98%	+592.14%	43.61B
BEONE MEDICINES AG	+5.60%	+10.21%	+16.76%	+85.72%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+33.39%	+8.85%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+21.31%	+53.37%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+37.75%	+126.84%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+6.24%	+18.87%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+78.59%	+30.30%	12.77B
Average	+1.90%	+6.32%	+85.64%	+116.60%	29.39B
Weighted average by Cap.	+2.54%	+6.10%	+104.25%	+140.79%

	2026 *	2027 *
Net sales	-	5M 526K 455K 425K 390K 734K 50.1M 745K 4.99M 1.96M 25.11M 1.98M 1.93M 83.02M
Net income	-86M -9.06M -7.83M -7.31M -6.71M -12.62M -862M -12.82M -85.82M -33.68M -432M -34M -33.26M -1.43B	-82M -8.63M -7.47M -6.97M -6.4M -12.03M -822M -12.22M -81.83M -32.12M -412M -32.42M -31.71M -1.36B
Net Debt	36M 3.79M 3.28M 3.06M 2.81M 5.28M 361M 5.37M 35.92M 14.1M 181M 14.23M 13.92M 598M	38M 4M 3.46M 3.23M 2.96M 5.58M 381M 5.67M 37.92M 14.88M 191M 15.02M 14.7M 631M